Literature DB >> 21036700

Androgen receptor-mTOR crosstalk is regulated by testosterone availability: implication for prostate cancer cell survival.

Yue Wu1, Rishi Raj Chhipa, Jinrong Cheng, Haitao Zhang, James L Mohler, Clement Ip.   

Abstract

BACKGROUND: Signaling between androgen receptor (AR) and mTOR may be crucial for prostate cancer cells to endure the low androgen and suboptimal nutrient conditions produced by androgen deprivation therapy.
MATERIALS AND METHODS: AR and mTOR cross-talk was examined in LNCaP cells exposed to either high or low testosterone. AR and mTOR activities were modified separately using either siRNA knockdown or specific chemical inhibitor. The biological significance of the reciprocal communication was assessed by susceptibility to glucose deprivation-induced cell death.
RESULTS: AR positively regulated mTOR activity in both low and high testosterone levels. TSC1 and TSC2, the two negative regulators of mTOR, may be involved since both were up-regulated by AR knockdown. Sub-baseline mTOR increased AR protein levels. However, this effect only occurred with low testosterone. More cells underwent apoptosis if AR function was inhibited during glucose deprivation, which significantly depressed mTOR activity.
CONCLUSION: The compensatory increase of AR function due to a repressed mTOR signal is advantageous for survival. Disrupting this loop at the time of initiation of androgen deprivation therapy may delay, or even prevent, the recurrence of prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21036700      PMCID: PMC4355915     

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  19 in total

Review 1.  When translation meets transformation: the mTOR story.

Authors:  J Averous; C G Proud
Journal:  Oncogene       Date:  2006-10-16       Impact factor: 9.867

2.  ARD1 stabilization of TSC2 suppresses tumorigenesis through the mTOR signaling pathway.

Authors:  Hsu-Ping Kuo; Dung-Fang Lee; Chun-Te Chen; Mo Liu; Chao-Kai Chou; Hong-Jen Lee; Yi Du; Xiaoming Xie; Yongkun Wei; Weiya Xia; Zhang Weihua; Jer-Yen Yang; Chia-Jui Yen; Tzu-Hsuan Huang; Minjia Tan; Gang Xing; Yingming Zhao; Chien-Hsing Lin; Shih-Feng Tsai; Isaiah J Fidler; Mien-Chie Hung
Journal:  Sci Signal       Date:  2010-02-09       Impact factor: 8.192

3.  Post-transcriptional regulation of the androgen receptor by Mammalian target of rapamycin.

Authors:  Bekir Cinar; Arrigo De Benedetti; Michael R Freeman
Journal:  Cancer Res       Date:  2005-04-01       Impact factor: 12.701

Review 4.  Bicalutamide: clinical pharmacokinetics and metabolism.

Authors:  Ian D Cockshott
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 5.  The effects of androgen deprivation on the prostate gland: cell death mediated by vascular regression.

Authors:  R Buttyan; M A Ghafar; A Shabsigh
Journal:  Curr Opin Urol       Date:  2000-09       Impact factor: 2.309

6.  Phosphatidylinositol 3-kinase/Akt pathway regulates tuberous sclerosis tumor suppressor complex by phosphorylation of tuberin.

Authors:  Han C Dan; Mei Sun; Lin Yang; Richard I Feldman; Xue-Mei Sui; Chien Chen Ou; Mark Nellist; Raymond S Yeung; Dicky J J Halley; Santo V Nicosia; Warren J Pledger; Jin Q Cheng
Journal:  J Biol Chem       Date:  2002-07-11       Impact factor: 5.157

7.  WD40 protein FBW5 promotes ubiquitination of tumor suppressor TSC2 by DDB1-CUL4-ROC1 ligase.

Authors:  Jian Hu; Sima Zacharek; Yizhou Joseph He; Hyun Lee; Stuart Shumway; Robert J Duronio; Yue Xiong
Journal:  Genes Dev       Date:  2008-04-01       Impact factor: 11.361

8.  Chemotherapeutic sensitization by endoplasmic reticulum stress: increasing the efficacy of taxane against prostate cancer.

Authors:  Yue Wu; Melissa Fabritius; Clement Ip
Journal:  Cancer Biol Ther       Date:  2009-02-01       Impact factor: 4.742

9.  Molecular determinants of resistance to antiandrogen therapy.

Authors:  Charlie D Chen; Derek S Welsbie; Chris Tran; Sung Hee Baek; Randy Chen; Robert Vessella; Michael G Rosenfeld; Charles L Sawyers
Journal:  Nat Med       Date:  2003-12-21       Impact factor: 53.440

10.  Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival.

Authors:  Y Wang; M Mikhailova; S Bose; C-X Pan; R W deVere White; P M Ghosh
Journal:  Oncogene       Date:  2008-09-08       Impact factor: 9.867

View more
  21 in total

1.  Remarkable inhibition of mTOR signaling by the combination of rapamycin and 1,4-phenylenebis(methylene)selenocyanate in human prostate cancer cells.

Authors:  Nicole D Facompre; Indu Sinha; Karam El-Bayoumy; John T Pinto; Raghu Sinha
Journal:  Int J Cancer       Date:  2012-03-20       Impact factor: 7.396

Review 2.  Molecules targeting the androgen receptor (AR) signaling axis beyond the AR-Ligand binding domain.

Authors:  N G R Dayan Elshan; Matthew B Rettig; Michael E Jung
Journal:  Med Res Rev       Date:  2018-11-22       Impact factor: 12.944

3.  mTOR inhibitors for treatment of low-risk prostate cancer.

Authors:  Michael A Liss; Lanette Rickborn; John DiGiovanni; Dean Bacich; Linda A DeGraffenried; Manish Parihar; Ian M Thompson; Zelton Dave Sharp
Journal:  Med Hypotheses       Date:  2018-06-05       Impact factor: 1.538

4.  Metabolomic profiling identifies biochemical pathways associated with castration-resistant prostate cancer.

Authors:  Akash K Kaushik; Shaiju K Vareed; Sumanta Basu; Vasanta Putluri; Nagireddy Putluri; Katrin Panzitt; Christine A Brennan; Arul M Chinnaiyan; Ismael A Vergara; Nicholas Erho; Nancy L Weigel; Nicholas Mitsiades; Ali Shojaie; Ganesh Palapattu; George Michailidis; Arun Sreekumar
Journal:  J Proteome Res       Date:  2013-12-31       Impact factor: 4.466

5.  Maternal High-Fat Diet Consumption and Chronic Hyperandrogenemia Are Associated With Placental Dysfunction in Female Rhesus Macaques.

Authors:  Kelly Kuo; Victoria H J Roberts; Jessica Gaffney; Diana L Takahashi; Terry Morgan; Jamie O Lo; Richard L Stouffer; Antonio E Frias
Journal:  Endocrinology       Date:  2019-08-01       Impact factor: 4.736

6.  Cotargeting Androgen Receptor Splice Variants and mTOR Signaling Pathway for the Treatment of Castration-Resistant Prostate Cancer.

Authors:  Minoru Kato; Carmen A Banuelos; Yusuke Imamura; Jacky K Leung; Daniel P Caley; Jun Wang; Nasrin R Mawji; Marianne D Sadar
Journal:  Clin Cancer Res       Date:  2015-12-28       Impact factor: 12.531

Review 7.  Emerging critical role of molecular testing in diagnostic genitourinary pathology.

Authors:  George J Netto; Liang Cheng
Journal:  Arch Pathol Lab Med       Date:  2012-04       Impact factor: 5.534

8.  Resistance to the mTOR-inhibitor RAD001 elevates integrin α2- and β1-triggered motility, migration and invasion of prostate cancer cells.

Authors:  I Tsaur; J Makarević; E Juengel; M Gasser; A-M Waaga-Gasser; M Kurosch; M Reiter; S Wedel; G Bartsch; A Haferkamp; C Wiesner; R A Blaheta
Journal:  Br J Cancer       Date:  2012-07-10       Impact factor: 7.640

9.  Prenatal testosterone-induced fetal growth restriction is associated with down-regulation of rat placental amino acid transport.

Authors:  Kunju Sathishkumar; Rebekah Elkins; Vijayakumar Chinnathambi; Haijun Gao; Gary D V Hankins; Chandra Yallampalli
Journal:  Reprod Biol Endocrinol       Date:  2011-08-03       Impact factor: 5.211

10.  Metabolomic profiling reveals a role for androgen in activating amino acid metabolism and methylation in prostate cancer cells.

Authors:  Nagireddy Putluri; Ali Shojaie; Vihas T Vasu; Srilatha Nalluri; Shaiju K Vareed; Vasanta Putluri; Anuradha Vivekanandan-Giri; Jeman Byun; Subramaniam Pennathur; Theodore R Sana; Steven M Fischer; Ganesh S Palapattu; Chad J Creighton; George Michailidis; Arun Sreekumar
Journal:  PLoS One       Date:  2011-07-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.